The oligodynamic action or the antimicrobial activity of small amounts of metal has been known for a long time and is the basis for the development of many metal coordination therapeutic agents. For example, silver sulfadiazine has been reported to exhibit antiherpes and antitreponemal properties, and has been used extensively for the treatment of burn patients. 1 Besides the use of heavy metals as antibiotics, they are also employed in the design of cytotoxic compounds. The current treatments for cell proliferative diseases such as cancer employ metal coordination complexes where such complexes inhibit DNA replication and cell division. One of the most prominent and promising metal-based cytotoxic agent that proved to have clinical benefits is arsenic trioxide (As 2 O 3 ). 2 This compound has been used with remarkable clinical success as a demethylation antileukemic agent for the treatment of acute promyelocytic leukemia (APL) and in combination with imatinib mesylate (Gleevec, STI571) for the treatment of chronic myelogenous leukaemia (CML). 2 Arsenic trioxide was also found to be potent even in patients who relapsed after alltrans-retinoic acid (ATRA)-resistant APL. 2 Ionic silver substances are resurging again in popularity due to the fact that silver at low concentrations has no toxicity, mutagenicity or carcinogenic activities compared to other heavy metals. 1 The only known condition, resulting from chronic exposure to high levels of silver for a prolonged period of time in humans is argyria, a permanent bluish-gray discoloration of the skin, which is an esthetic benign condition with no known pathological changes or inflammatory reactions.
1 Surprisingly, despite the intense interest in the use of heavy metals in the treatment of cancer, there is a paucity in the implementation of silver (I) chelates as cytotoxic agents. 3 Recently, the author has reported on the antimicrobial properties and mechanism of action of silver (I)-tartaric and glutamic acids chelates, and the results suggested that the active agent is the silver chelates rather than free silver ions, demonstrating that the effect of silver might be linked to cell DNA unwinding. 4 Prompted by these encouraging results, and the interest in the potential use of these chelates as anticancerous agents, the aims of the present study are three-fold: (a) to explore the cytotoxicity of silver (I)-tartaric acid chelate given the title name Aliargentumycine by determining its in vitro antitumor activities on acute myeloid leukemia HL-60 and lymphoid leukemia Jurkat human cell lines, (b) to evaluate its toxicity on normal human peripheral blood mononuclear cells (HPBMNC) and (c) to determine its mechanism of cytotoxicity.
Aliargentumycine was prepared according to a previously described procedure. 4 Clear colorless single crystals of Aliargentumycine were prepared by allowing the ionic mixture to stand at ambient temperature in the dark until crystals were formed. The mixture was then filtered vacuumed and the crystals were collected. The purity of Aliargentumycine for carbon and hydrogen was determined by a combustion/gravimetric method, while for silver atomic absorption spectroscopy (AA) was employed. The data obtained on carbon and hydrogen were found to agree with the calculated ones within 70.4%. The error for silver was found to be 71.01%, which is within the error of the AA instrument, 71.7%.
The cytotoxicity of Aliargentumycine and arsenic trioxide was assessed via trypan blue-exclusion method. The results of cytotoxicity for both Aliargentumycine (AAgM) and arsenic trioxide (AsTO) obtained on HL-60 and Jurkat in terms of concentration in micromolars are depicted in Figures 1a and b, respectively. On the average, AAgM induced one order of magnitude reduction of the original cell count on both HL-60 and Jurkat when compared with free silver ions, and at lower concentrations, silver ions did not exhibit any cytotoxic effects when compared to AAgM (data not shown). Similar results were obtained on the antimicrobial activities of silver (I) tartaric and glutamic acids chelates. 4 Examination of the data of Figure 1 5 cells/well in 96-well tissue culture plates in the presence or absence of Aliargentumycine and arsenic trioxide with serial doubling dilutions. The plates were incubated at 371C in a CO 2 incubator for 48 h before harvesting and counting. Cells were then collected, mixed with equal volume of PBS containing 0.4% trypan blue dye and manually counted. The results shown are the means7s.e. of three independent experiments. Test culture was also inoculated with the present reagents without the presence of drugs. All controls turned out as expected, validating the observations of the actual experiments. All reagents were pharmaceutically graded and were purchased from Sigma-Aldrich (Milwaukee, WI, USA). AAgM and AsTO were prepared as stock solutions in sterile deionized water and then diluted as desired in complete RPMI. C-RPMI included RPMI-1640 culture medium obtained from Gibco Invitrogen Co. (Carlsbad, CA, USA) where it was supplemented with 10% fetal bovine serum (Gibco Invitrogen Co.), 2 mM L-glutamine (Gibco) and 40 mg/ml gentamicin (EuroClone, Paignton, Devon, UK).
Letters to the Editor reveals that the cytotoxicity of AAgM exhibits an aberrant triphasic cytotoxicity profile. Phases I and III are characterized by cytotoxicity in the nanoconcentration and microconcentration ranges while Phase II is characterized by the absence of cytotoxicity in the intermediate range. These phases occur abruptly as the concentration of Aliargentumycine increases. Such a triphasic behavior is also observed in hormone coactivators (J Shay, December 2005, personal communication).
Throughout the concentration range studied, the results show that Jurkat requires higher concentrations of both drugs for inhibition in comparison with HL-60. The results on AsTO are in agreement with data obtained by other authors. 5 The inhibition of AsTO on Jurkat however ceases with further dilutions, contrary to that of HL-60 which continues with further dilutions (compare Figures 1b and a) . This behavior is not observed with AAgM on Jurkat where lower concentrations of AAgM remain cytotoxic. In addition, it can be inferred from Figure 1 that considering the range of concentration studied, overall AAgM gives better cytotoxicity at lower concentrations. Other drugs such as 6_mercaptopurine and 5-aza-2 0 -deoxycytidine (decitabine) show similar dependence on leukemia cells in that lower concentrations give better cytotoxicity. 6 This behavior is also observed with metronomic dosing of tumor angiogenesis drugs.
To give a more quantitative pharmacokinetic -pharmacodynamic predictor regarding the cytotoxic activities of Aliargentumycine, the area-under-the-concentration-curve for the time period over 24 h (AUC t424 ) was calculated. The linear trapezoidal rule was used to calculate the AUC t424 values. Regression models were then applied to the data. Multiple curve estimation procedure was employed, and the relative fit for each model was determined on the basis of the values of the correlation coefficient r 2 . The regression equations were then integrated and their sum was taken as the AUC t424 . Since interest in drug design lies within the nanomolar range, only the AUC t424 values in the nanomolar range were calculated, specifically Phase I for both cell lines.
The calculated AUC t424 for HL-60 were 4.20 and 5.45 for AAgM and AsTO, respectively, while for Jurkat 2.81 and 1.38 for the former and the latter. It can be concluded from these calculations that AsTO is more effective on HL-60 than AAgM while the opposite holds true for Jurkat. It is interesting to note that when comparing the ratio of AUC t424 for AAgM to AsTO for HL-60 and Jurkat, the values are 0.8 and 2 for HL-60 and Jurkat, respectively. One can see that for HL-60 both drugs have similar cytotoxic activities while for Jurkat the ratio is doubled in the case of AAgM, demonstrating its higher cytotoxic potency relative to AsTO.
Aliargentumycine's lack of cytotoxicity in Phase II might signal cell differentiation where malignant phenotype becomes benign. Differentiation therapy is observed with As 2 O 3 in APL cells, leading to clinical remissions. The ability of As 2 O 3 to cause differentiation was also reported in phase II clinical trial of patients suffering from advanced refractory multiple myelomaa B cell neoplasm. 7 The fact that AAgM did not exhibit any cytotoxicity in Phase II for both cell lines might indicate differentiation where cells might have reverted back to becoming nonmalignant, similar to As 2 O 3 and other experiments done on salamander cancers using silver. 1 Aberrant DNA hypermethylation-mediated gene is one of the most commonly occurring epigenetic events, and plays a decisive role in human carcinogenesis. Silencing of the proliferation-associated p15 gene is commonly associated with myelodysplastic syndrome. 6 Hence, drugs such as decitabine that inhibits DNA methylation is becoming very important in the fight of cancer. 6 The observed lack of cytotoxicity of AAgM in Phase II might be indicative that reversal of hypermethylation through p15 gene is present. Along these lines, it is also noteworthy to mention here that arsenic trioxide was found to upregulate the tumor suppressor p53 gene and activation of caspase-3 in gastric carcinoma. 8 Thus, it is prudent for future studies to identify other genes such as p15 and p53 to delineate the exact underlying mechanistic steps involved in the cytotoxicity of Aliargentumycine. It is also possible that the observed lack of cytotoxicity in Phase II is related to the loss of ability of cells to divide, leading to a growth arrest (J Shay, December 2005, personal communication).
To examine whether AAgM is less toxic on normal cells, HPBMNC obtained from healthy donors were tested. For comparative purposes, arsenic trioxide was also evaluated and the results are presented in Figure 2 . By comparing Figures 1 and  2 , it can be concluded that AAgM and arsenic trioxide are both less toxic to normal cells than malignant cells, and AAgM is less toxic than AsTO against normal cells (Figure 2 ). Equally important is the fact that the triphasic profile of AAgM in Figure 1 is absent in normal cells, implying that the mechanism of toxicity of AAgM is different for normal cells compared to malignant ones.
Apoptotic studies were conducted to determine the underlying mechanism of action of AAgM, and the results are shown in Figure 3 . Apoptosis was conducted by flow cytometric analyses of a TUNEL labeling procedure as described in an apoptosis kit manual purchased from Promega (Madison-WI, USA). Significant sensitivity towards induction of apoptosis by AAgM at concentrations of clinical interest is observed for both cell lines, Figure 3 . However, the sensitivity of apoptosis is different for the different cell lines being lower for HL-60 than for Jurkat for Phase I, while the opposite holds true for Phase III. It is also of significance to note that the frequency of apoptosis is also reflected and fingerprinted in the % inhibition results (compare Figures 1 and 3) . This is the first report in the literature to show that silver (I)-tartaric acid chelate induces apoptosis.
The interest in silver (I) chelates is two-fold: on the one side, they may constitute a new class of safer cytotoxic drugs, and on the other side they represent further attempt to elucidate the mechanism of action of antineoplastic d 10 cubic-face-centered metal complexes. With respect to organic and inorganic arsenicals such as arsenic trioxide, systemic toxicity is a major 
Figure 2
Effect of Aliargentumycine (filled bars) and arsenic trioxide (empty bars) on normal blood cells. Peripheral blood mononuclear cells (PBMNCs) prepared from healthy normal blood donors were purified over Ficoll Hypaque (Sigma Chemical Co., Saint Louis, MO, USA). Cells were stimulated with PHA-P at 10 mg/ml. PBMNCs were incubated in the presence of both drugs for 48 h. Cell survival was assessed via trypan blue-exclusion method. The results shown are the means7s.e. of three independent experiments.
Letters to the Editor problem, not to mention that these compounds can cause skin and lung cancer.
Albeit various robust methods and techniques have been employed to combat hematopoietic malignancies, there is still a deluge of caveats and a plethora of adverse side effects, including tubular necrosis, thrombocytopenia, nausea, peripheral and autonomic neuropathies, and many others related to pulmonary, reproductive and endocrine and even cardiac arrest, especially at high doses. These induced side effects significantly impact the quality of life of the patient and dramatically influence the patient's compliance with the treatment regimen. On the other hand, it is possible to design safer silver-based cytotoxic drugs for the treatment of hematopoietic malignancies that can be integrated into the systemic treatment of cancer armamentarium, thereby reducing and alleviating the sundry of adverse side effects associated with the current cytotoxic drugs used for hematopoietic malignancies, making silver an excellent candidate for alternative therapy. Particularly, combinations of Aliargentumycine with standard cytotoxic drugs, applied possibly in a specific sequence, may have the potential for significant synergistic cytotoxicity that can be maneuvered to significantly reduce the concentrations of such traditional drugs. The most important outcomes of the present work are the fact that the present moiety has excellent cytotoxicity and its potency extends to the nanoconcentration range. This is the first report in the literature to show such findings. The exceptionally low toxicity of silver (I) at the present concentrations reported here, the significant in vitro cytotoxicity of Aliargentumycine against leukemia cell lines, and the intriguing lack of cytotoxicity in Phase II collectively warrant further studies.
The JAK2 V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders Leukemia (2008) The discovery of the JAK2 V617F somatic mutation was a tremendous breakthrough for the understanding of the physiopathology of the myeloproliferative disorders (MPD) and contributed to define more accurately these diseases. 1 However, there is no information on the time of appearance of this acquired event and the period needed for the development of the disease, the presence of the mutation being usually tested for a suspected MPD. Figure 3 Percentage (%) of apoptosis of Aliargentumycine (AAgM) on HL-60 (dotted bars) and Jurkat (diagonal bars) analyzed by flow cytometry. Cells were treated for 48 h with AAgM. Following treatment, apoptotic cells were measured by flow cytometric analyses. Cells were seeded at 1 Â 10 5 cells/ml and were treated with Aliargentumycine to induce apoptosis at 0.03, 4 and 60 mM for Phases I, II and III, respectively. Positive and negative controls were employed by incubating HL-60 cells at 451C for 45 min (Positive) and by maintaining the cells in media without any cytotoxic drugs (Control), respectively. Detection of apoptosis was done by the DeadEnd Colorimetric TUNEL assay for the detection of apoptosis in cultured cells as described in Promega kit.
